Differential upregulation of human 2′5′OAS genes on systemic sclerosis: Detection of increased basal levels of OASL and OAS2 genes through a qPCR based assay

Autoimmunity

Volumn 47, Issue 2, 2014, Pages 119-126

  De Freitas Almeida, Gabriel Magno ^a   Oliveira, Danilo Bretas De ^a   Botelho, Lucas Moreira ^a   Silva, Ludmila Karen Dos Santos ^a   Guedes, Antônio Carlos Martins ^a   Santos, Flávia Patrícia Sena Teixeira ^a   Bonjardim, Cláudio Antônio ^a   Ferreira, Paulo César Peregrino ^a   Kroon, Erna Geessien ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

2 5 Oligoadenylate synthetases; Autoimmunities; Homeostasis; Interferon; Scleroderma

Indexed keywords

2',5'-OLIGOADENYLATE SYNTHETASE; ADULT; AGED; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; ISOENZYMES; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; ORGAN SPECIFICITY; POLYMERASE CHAIN REACTION; PRIMARY CELL CULTURE; SCLERODERMA, SYSTEMIC; UP-REGULATION;

EID: 84894559265     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2013.866102     Document Type: Article

References (28)

1. Kristiansen, H., H. H. Gad, S. Eskildsen-Larsen, et al. 2011. The oligoadenylate synthetase family: An ancient protein family with multiple antiviral activities. J. Interferon Cytokine Res. 31: 41-47.
2. Hovanessian, A. G., R. E. Brown, and I. M. Kerr. 1977. Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from interferon-treated cells. Nature. 268: 537-540.
3. Kristiansen, H., C. A. Scherer, M. McVean, et al. 2010. Extracellular 20-50 oligoadenylate synthetase stimulates RNase L-independent antiviral activity: A novel mechanism of virusinduced innate immunity. J. Virol. 84: 11898-11904.
4. Marques, J., J. Anwar, S. Eskildsen-Larsen, et al. 2008. The p59 oligoadenylate synthetase-like protein possesses antiviral activity that requires the C-terminal ubiquitin-like domain. J. Gen. Virol. 89: 2767-2772.
5. Eskildsen, S., J. Justesen, M. H. Schierup, and R. Hartmann. 2003. Characterization of the 20-50-oligoadenylate synthetase ubiquitinlike family. Nucl. Acids Res. 31: 3166-3173.
6. Hovnanian, A., D. Rebouillat, M. G. Mattei, et al. 1998. The human 20,50-oligoadenylate synthetase locus is composed of three distinct genes clustered on chromosome 12q24.2 encoding the 100-, 69-, and 40-kDa forms. Genomics. 52: 267-277.
7. Witt, P. L., I. Marie, N. Robert, et al. 1993. Isoforms p69 and p100 of 20,50-oligoadenylate synthetase induced differentially by interferons in vivo and in vitro. J. Interferon Res. 13: 17-23.
8. Melchjorsen, J., H. Kristiansen, R. Christiansen, et al. 2009. Differential regulation of the OASL and OAS1 genes in response to viral infections. J. Interferon Cytokine Res. 29: 199-207.
9. Rebouillat, D., A. Hovnanian, G. David, et al. 2000. Characterization of the gene encoding the 100-kDa form of human 20,50 oligoadenylate synthetase. Genomics. 70: 232-240.
10. Wang, Q., and G. Floyd-Smith. 1997. The p69/71 2-5A synthetase promoter contains multiple regulatory elements required for interferon-alpha-induced expression. DNA Cell. Biol. 16: 1385-1394.
11. Dan, M., D. Zheng, L. L. Field, and V. Bonnevie-Nielsen. 2012. Induction and activation of antiviral enzyme 20,50-oligoadenylate synthetase by in vitro transcribed insulin mRNA and other cellular RNAs. Mol. Biol. Rep. 39: 7813-7822.
12. Ghosh, A., S. N. Sarkar, T. M. Rowe, and G. C. Sen. 2001. A specific isozyme of 20-50 oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family. J. Biol. Chem. 276: 25447-25455.
13. Dugan, J. W., A. Albor, L. David, et al. 2009. Nucleotide oligomerization domain-2 interacts with 20-50-oligoadenylate synthetase type 2 and enhances RNase-L function in THP-1 cells. Mol. Immunol. 47: 560-566.
14. Lee, M. S., B. Kim, G. T. Oh, and Y. J. Kim. 2013. OASL1 inhibits translation of the type I interferon-regulating transcription factor IRF7. Nat. Immunol. 14: 346-355.
15. Cagliani, R., M. Fumagalli, F. R. Guerini, et al. 2012. Identification of a new susceptibility variant for multiple sclerosis in OAS1 by population genetics analysis. Hum. Genet. 131: 87-97.
16. Ye, S., Q. Guo, J. P. Tang, et al. 2007. Could 2050-oligoadenylate synthetase isoforms be biomarkers to differentiate between disease flare and infection in lupus patients A pilot study. Clin. Rheumatol. 26: 186-190.
17. Coelho, L. F., J. G. De Oliveira, D. B. De Oliveira, et al. 2007. Increased expression of 2050oligoadenylate synthetase and double-stranded RNA dependent protein kinase messenger RNAs on affected skin of systemic sclerosis patients. Arch. Dermatol. Res. 299: 259-262.
18. De Oliveira, D. B., G. M. Almeida, A. C. Guedes, et al. 2011. Basal activation of type I interferons (Alpha2 and Beta) and 2050OAS genes: Insights into differential expression profiles of interferon system components in systemic sclerosis. Int. J. Rheumatol. 2011: 275617.
19. Chizzolini, C., N. C. Brembilla, E. Montanari, and M. E. Truchetet. 2011. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun. Rev. 10: 276-281.
20. Denton, C. P., and C. M. Black. 2004. Scleroderma-clinical and pathological advances. Best Pract. Res. Clin. Rheumatol. 18: 271-290.
21. Abraham, D. J., and J. Varga. 2005. Scleroderma: From cell and molecular mechanisms to disease models. Trends Immunol. 26: 587-595.
22. Hikami, K., Y. Ehara, M. Hasegawa, et al. 2008. Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis. Biochem. Biophys. Res. Commun. 373: 403-407.
23. Assassi, S., M. D. Mayes, F. C. Arnett, et al. 2010. Systemic sclerosis and lupus: Points in an interferon-mediated continuum. Arthritis Rheum. 62: 589-598.
24. Molteni, M., S. Della Bella, B. Mascagni, et al. 1999. Increased interferon-gamma (IFN-g) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynauds phenomenon. Clin. Exp. Immunol. 116: 164-168.
25. Valentini, G., A. Baroni, K. Esposito, et al. 2001. Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J. Clin. Immunol. 21: 210-217.
26. Coelho, L. F., J. G. De Oliveira, and E. G. Kroon. 2008. Interferons and scleroderma-A new clue to understanding the pathogenesis of scleroderma Immunol. Lett. 118: 110-115.
27. Jaitin, D. A., L. C. Roisman, E. Jaks, et al. 2006. Inquiring into the differential action of interferons (IFNs): An IFN-a2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol. Cell. Biol. 26: 1888-1897.
28. Francois-Newton, V., G. Magno De Freitas Almeida, B. Payelle-Brogard, et al. 2011. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS One. 6: E22200.